GSK Begins Shipping Doses Of Quadrivalent Influenza Vaccines To US For 2023-24 Flu Season

RTTNews | 473 dias atrás
GSK Begins Shipping Doses Of Quadrivalent Influenza Vaccines To US For 2023-24 Flu Season

(RTTNews) - GSK plc (GSK, GSK.L) announced Thursday it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2023-24 flu season.

This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA).

GSK expects to distribute over 40 million doses of its influenza vaccine to the US market. Both Flulaval Quadrivalent and Fluarix Quadrivalent will be available in a 0.5mL, single-dose, pre-filled syringe, and are indicated for patients six months and older.

CDC recommends an annual flu vaccination for anyone aged six months and older who does not have contraindications.

read more
GSK Lifts FY23 Outlook As Q3 Profit From Cont. Opns Surges

GSK Lifts FY23 Outlook As Q3 Profit From Cont. Opns Surges

British drug major GSK Plc on Wednesday lifted its fiscal 2023 forecast for earnings and sales after reporting higher third-quarter profit on continuing operations basis. The results were benefited by vaccines' performance, mainly the US launch of Arexvy, the world's first RSV vaccine. Total profit for the quarter, meanwhile, plunged from last year on the absence of prior year's hefty gain.
RTTNews | 362 dias atrás
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | 433 dias atrás
GSK, SCYNEXIS Ink Exclusive Licence Agreement For Brexafemme

GSK, SCYNEXIS Ink Exclusive Licence Agreement For Brexafemme

GSK plc (GSK, GSK.L) and SCYNEXIS, Inc. (SCYX) announced Thursday they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC).
RTTNews | 578 dias atrás
FDA Approves GSK's Drug For Anemia Caused By CKD For Adults On Dialysis

FDA Approves GSK's Drug For Anemia Caused By CKD For Adults On Dialysis

The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval.
RTTNews | 634 dias atrás
FDA Approves GSK's Vaccine For Use In Pregnancy To Prevent Whooping Cough In Infants

FDA Approves GSK's Vaccine For Use In Pregnancy To Prevent Whooping Cough In Infants

The FDA has approved GSK plc's Boostrix vaccine for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger than two months of age. The agency noted that Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]), when given during pregnancy, boosts antibodies in the mother.
RTTNews | 749 dias atrás
CAC 40 Rallies After Israel's Calibrated Attack On Iran

CAC 40 Rallies After Israel's Calibrated Attack On Iran

French stocks rallied on Monday after Israel pounded Iran with a series of airstrikes early Saturday in retaliation for the barrage of ballistic missiles the Islamic Republic fired upon Israel on October 1.
RTTNews | 4 h 12 min atrás